Affordable wellbeing EXTRA 2 € OFF EVERY 20 € SPENT - Expires in: 
Subscribe to our newsletter!
JOINART SIR 1.6% 2ML 3PCS
Availability Out of stock
Special Price €141.01 -18% Regular Price €172.00
The price was: €141.01
Discover the product
Description JOINART SIR 1.6% 2ML 3PCS
FENIXPHARMA
< b>JOINART
32 mg/2 ml
Hyaluronic acid sodium salt 1.6%
< div align=justify>Directions
Joinart is a substitute for synovial fluid in joints affected by degenerative or mechanical arthropathy, causing pain or mobility reduced.
Description
Joinart is a medical device with CE marking compliant with the MDD93/42/EEC directive, containing 16 mg/ml of hyaluronic acid obtained by fermentation from a high molecular weight fraction (> 1500 kDa) and not chemically modified.
Joinart is a clear, sterile, non-pyrogenic and viscoelastic solution supplied in a 2 ml syringe. Hyaluronic acid is a natural polysaccharide present in many human tissues, in particular in synovial fluid, and acts in the joints both as a lubricant of cartilage and ligaments and as a shock absorber. According to many studies, injections of hyaluronic acid into joints affected by osteoarthritis restore the viscosity of the joints. and elasticity of the synovial fluid, with a consequent alleviation of pain and an improvement in mobility. of the joint.
Joinart acts only at the level of the joint into which it is injected, without exerting any systemic action.
Composition
Main component sterile hyaluronic acid sodium salt 1.6% . Other components: sodium chloride, sodium phosphate and water for injections.
Packaging
Joinart is supplied in a glass syringe containing 32 mg of hyaluronic acid in 2 ml of sodium chloride buffered saline solution, packaged in a blister.
The contents of the syringe are sterilized with moist heat.
Instructions for use
Remove any joint effusion before injecting Joinart; the same needle must be used for removal of the effusion and injection of Joinart. Remove the protective cap of the syringe, paying particular attention to avoid contact with the opening.
Firmly screw the needle with a diameter between 18 and 22 G to the Luer type closure collar to ensure a watertight seal.
Before injection treat the site with an appropriate antiseptic solution. Inject Joinart using an aseptic technique. Inject only into the cavity joint.
Administration
Joinart must be administered weekly for a total of three weeks or in any case according to the medical prescription.
Warnings< /b>
• The contents of the pre-filled syringe are sterile.
The syringe is packaged in a sterile blister.
The surface of the syringe is not smooth. sterile.
• Do not use Joinart after the expiry date shown on the package.
• Do not use Joinart if the package or syringe is open or damaged.
• The injection site must be on healthy skin.
• Do not inject vascularly. Do not inject outside the cavity. joint, in the tissues or synovial capsules.
• Joinart is not been tested in pregnant or breastfeeding women.
• Joinart is disposable and must not be resterilized.
• Avoid the simultaneous administration of Joinart with other products for intra-articular use in order to prevent any possible interaction.
• Do not administer Joinart in the presence of abundant intra-articular effusion.
• Once the package has been opened, Joinart must be used immediately and disposed of according to current regulations.
• Keep out of reach of children.
• As with any invasive treatment of the joint, the patient is recommended to avoid all activities. intense physical activity for the first 2-3 days after the injection.
Contraindications
Must not be administered:
• to patients with proven sensitivity to hyaluronic acid and related compounds;
• in case of infection or skin disease near the injection site;
• if the joint is infected or severely inflamed.
Side effects
Some transient side reactions may occur following the injection of Joinart, such as pain, stiffness, sensation of heat, redness or swelling.
These secondary manifestations can be alleviated by applying ice to the treated joint. Normally they disappear after a short time. If symptoms persist, contact a doctor. As with any invasive treatment of the joint, septic arthritis could occur if appropriate precautions are not observed during the injection or the injection site is not aseptic.
Storage and expiration
Joinart must be stored in the original packaging at a temperature between 0 and 25°C, protected from direct sunlight and frost. The expiration date is indicated on the package.
Cod.
0000000000001
0000000000002
< b>JOINART
32 mg/2 ml
Hyaluronic acid sodium salt 1.6%
< div align=justify>Directions
Joinart is a substitute for synovial fluid in joints affected by degenerative or mechanical arthropathy, causing pain or mobility reduced.
Description
Joinart is a medical device with CE marking compliant with the MDD93/42/EEC directive, containing 16 mg/ml of hyaluronic acid obtained by fermentation from a high molecular weight fraction (> 1500 kDa) and not chemically modified.
Joinart is a clear, sterile, non-pyrogenic and viscoelastic solution supplied in a 2 ml syringe. Hyaluronic acid is a natural polysaccharide present in many human tissues, in particular in synovial fluid, and acts in the joints both as a lubricant of cartilage and ligaments and as a shock absorber. According to many studies, injections of hyaluronic acid into joints affected by osteoarthritis restore the viscosity of the joints. and elasticity of the synovial fluid, with a consequent alleviation of pain and an improvement in mobility. of the joint.
Joinart acts only at the level of the joint into which it is injected, without exerting any systemic action.
Composition
Main component sterile hyaluronic acid sodium salt 1.6% . Other components: sodium chloride, sodium phosphate and water for injections.
Packaging
Joinart is supplied in a glass syringe containing 32 mg of hyaluronic acid in 2 ml of sodium chloride buffered saline solution, packaged in a blister.
The contents of the syringe are sterilized with moist heat.
Instructions for use
Remove any joint effusion before injecting Joinart; the same needle must be used for removal of the effusion and injection of Joinart. Remove the protective cap of the syringe, paying particular attention to avoid contact with the opening.
Firmly screw the needle with a diameter between 18 and 22 G to the Luer type closure collar to ensure a watertight seal.
Before injection treat the site with an appropriate antiseptic solution. Inject Joinart using an aseptic technique. Inject only into the cavity joint.
Administration
Joinart must be administered weekly for a total of three weeks or in any case according to the medical prescription.
Warnings< /b>
• The contents of the pre-filled syringe are sterile.
The syringe is packaged in a sterile blister.
The surface of the syringe is not smooth. sterile.
• Do not use Joinart after the expiry date shown on the package.
• Do not use Joinart if the package or syringe is open or damaged.
• The injection site must be on healthy skin.
• Do not inject vascularly. Do not inject outside the cavity. joint, in the tissues or synovial capsules.
• Joinart is not been tested in pregnant or breastfeeding women.
• Joinart is disposable and must not be resterilized.
• Avoid the simultaneous administration of Joinart with other products for intra-articular use in order to prevent any possible interaction.
• Do not administer Joinart in the presence of abundant intra-articular effusion.
• Once the package has been opened, Joinart must be used immediately and disposed of according to current regulations.
• Keep out of reach of children.
• As with any invasive treatment of the joint, the patient is recommended to avoid all activities. intense physical activity for the first 2-3 days after the injection.
Contraindications
Must not be administered:
• to patients with proven sensitivity to hyaluronic acid and related compounds;
• in case of infection or skin disease near the injection site;
• if the joint is infected or severely inflamed.
Side effects
Some transient side reactions may occur following the injection of Joinart, such as pain, stiffness, sensation of heat, redness or swelling.
These secondary manifestations can be alleviated by applying ice to the treated joint. Normally they disappear after a short time. If symptoms persist, contact a doctor. As with any invasive treatment of the joint, septic arthritis could occur if appropriate precautions are not observed during the injection or the injection site is not aseptic.
Storage and expiration
Joinart must be stored in the original packaging at a temperature between 0 and 25°C, protected from direct sunlight and frost. The expiration date is indicated on the package.
Cod.
0000000000001
0000000000002
